Dr. Everett E. Vokes, MD is an internationally renowned expert with over 40 years of experience in the treatment of head and neck and lung cancers. Currently, he serves as the John E. Ultmann Distinguished Service Professor of Medicine, Chair for the Department of Medicine, and Physician-in-Chief at the University of Chicago, where he leads the Department of Medicine’s focus on the discovery and delivery of personalized medicine. From 2021-2022, he served as the President of the American Society of Clinical Oncology (ASCO). Dr. Vokes is a widely published author with over 450 papers and 80 book chapters, has served on numerous advisory committees and editorial boards, and has received many awards, including the ASCO Translational Research Professorship and recognition as a “Giant of Cancer Care”. Dr. Vokes completed his medical degree at the University of Bonn Medical School and residency in internal medicine at Ravenswood Hospital Medical Center in Chicago and at the University of Southern California in Los Angeles. 

Josep Tabernero is a distinguished expert in medical oncology currently serving as the Director of Vall d’Hebron Institute of Oncology (VHIO) and Head of the Medical Oncology Department at Vall d’Hebron University Hospital. His research centers on molecular targeted therapies, targeting specific oncoproteins and novel immunotherapies to advance and accelerate more effective personalized cancer medicines for patients displaying genetic lesions or pathway dysregulation. He has expertise in predictive markers of response to anti-cancer therapies and innovative preclinical models (patient-derived xenografts and organoids) for studying tumor development. Josep served as President of the European Society for Medical Oncology (ESMO) from 2018-2019 and has been an active member of its Executive Board and multiple educational and scientific committees across ESMO, AACR, and ASCO. He actively contributes to various scientific committees and prestigious journals, driving progress in oncology globally. He is the Chair of Cancer Core Europe and a member of the Board of Directors of the Organisation of European Cancer Institutes (OECI).

Mikael Dolsten is a seasoned and accomplished industry executive with extensive global pharmaceutical management experience. He most recently served as the Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer, Inc., where he led global R&D strategy and portfolio advancement for more than 16 years and was instrumental in the development of breakthrough innovations spanning small molecules, biologics, gene therapies, and vaccines. His leadership has shaped portfolios at Boehringer Ingelheim, AstraZeneca, and Wyeth, and he has contributed to corporate transactions exceeding $100 billion in value. He has also contributed to more than 36 drug approvals, many representing breakthroughs in the oncology field, during his tenure as leader of Pfizer global R&D-Medical. Mikael currently serves on the public boards of Agilent Technologies and Rocket Pharmaceuticals and holds advisory roles with leading investment and innovation groups including Blackstone Life Sciences, GV (formerly Google Ventures), Bain & Company, and Formation Bio. He is a Visiting Professor at Lund University and a member of the Royal Swedish Academy of Engineering Sciences, and has advised U.S. and U.K. leadership on public health and pandemic preparedness. He received a Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden.